Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

We recently found that MLL-rearranged acute lymphoblastic leukemias (MLL) have a unique gene expression profile including high level expression of the receptor tyrosine kinase FLT3. We hypothesized that FLT3 might be a therapeutic target in MLL and found that 5 of 30 MLLs contain mutations in the activation loop of FLT3 that result in constitutive activation. Three are a newly described deletion of I836 and the others are D835 mutations. The recently described FLT3 inhibitor PKC412 proved cytotoxic to Ba/F3 cells dependent upon activated FLT3 containing either mutation. PKC412 is also differentially cytotoxic to leukemia cells with MLL translocations and FLT3 that is activated by either overexpression of the wild-type receptor or mutation. Finally, we developed a mouse model of MLL and used bioluminescent imaging to determine that PKC412 is active against MLL in vivo.

[1]  C. Pui,et al.  Biology and Clinical Significance of Cytogenetic Abnormalities in Childhood Acute Lymphoblastic Leukemia , 1990 .

[2]  H. Beug,et al.  MLL–ENL cooperates with SCF to transform primary avian multipotent cells , 2002, The EMBO journal.

[3]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[4]  M. Eguchi,et al.  Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia , 2000, Leukemia.

[5]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[6]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[7]  D. Birnbaum,et al.  Expression of the FLT3 gene in human leukemia-lymphoma cell lines. , 1994, Leukemia.

[8]  T Friedmann,et al.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Birnbaum,et al.  Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. , 1995, Leukemia.

[10]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[11]  A. Harris,et al.  Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Naoe,et al.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain , 2002, Oncogene.

[13]  S. Goff,et al.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. , 1995, Immunity.

[14]  S. McCullough,et al.  Sensitivity of FISH in detection of MLL translocations , 2000, Genes, chromosomes & cancer.

[15]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[16]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[17]  C. Pui,et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.

[18]  Intensified therapy for infants with acute lymphoblastic leukemia , 1997, Cancer.

[19]  S. Raimondi,et al.  Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. , 1992, Science.

[20]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[21]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[22]  D. Birnbaum,et al.  Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. , 1991, Oncogene.

[23]  D. Pardoll,et al.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations , 1991, Cell.

[24]  G. Mcmahon,et al.  SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. , 2002, Blood.

[25]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[26]  J J Shuster,et al.  Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. , 1991, Blood.

[27]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[28]  F. Cotter,et al.  BCL‐2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;ll)(q21;q23) translocation , 1995, British journal of haematology.

[29]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[30]  T. Hawley,et al.  Versatile retroviral vectors for potential use in gene therapy. , 1994, Gene therapy.

[31]  D. Arthur,et al.  Establishment of a leukemic cell model for studying human pre-B to B cell differentiation. , 1989, Journal of immunology.

[32]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[33]  C. Bartram,et al.  The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin‐7 , 1994, British journal of haematology.

[34]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Donna Neuberg,et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.

[37]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[38]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[39]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[40]  J. Rowley,et al.  The critical role of chromosome translocations in human leukemias. , 1998, Annual review of genetics.

[41]  E. Lander,et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.

[42]  S. Korsmeyer,et al.  Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. , 1993, Blood.

[43]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[44]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[45]  T. Golub,et al.  The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. , 2002, Cancer cell.

[46]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[47]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[48]  M. K. Hibbard,et al.  PLAG1 fusion oncogenes in lipoblastoma. , 2000, Cancer research.